# Sources — Wilma Rudolph

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 4, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Norwood A. “Wilma Rudolph,” National Women’s History Museum, 2017. Supports her birth on June 23, 1940, in Saint Bethlehem, Tennessee, as one of 22 children; polio and scarlet fever, a leg brace, and her family removing the brace to massage the leg; her own words, “my doctor told me I would never walk again. My mother told me I would. I believed my mother”; moving with the brace by eight; the 1956 relay bronze and three gold medals in Rome in 1960, the first American woman to win three track and field golds at one Games; the organization she founded for amateur athletes; and that she died of a brain tumor on November 12, 1994. https://www.womenshistory.org/education-resources/biographies/wilma-rudolph
2. U.S. Olympic & Paralympic Museum. “Wilma Rudolph: Olympic Sprinter,” U.S. Olympic & Paralympic Hall of Fame. Supports her premature birth at 4½ pounds in Saint Bethlehem; double pneumonia and scarlet fever at about four; polio with a paralyzed left leg; a metal brace for several years and a specially made shoe; weekly bus trips with her mother to Nashville, a 90-minute round trip, “to the closest doctor they could find to treat Rudolph in the segregated south”; her autobiography’s account of being told she would never walk; running by eleven; the 1956 and 1960 medals; and that she had brain cancer and throat cancer and died in 1994 at 54. https://usopm.org/Wilma-Rudolph
3. Lovett BL. “Wilma Rudolph (1940-1994) and the TSU Tigerbelles,” *Tennessee Encyclopedia*, Tennessee Historical Society. Supports her birth on June 23, 1940, in Clarksville as the twentieth of twenty-two children; a number of childhood diseases before polio; leg braces from six until ten; the Tigerbelles and the Rome gold medals; her return to Tennessee in 1992 as a vice president of Nashville’s Baptist Hospital; that two years later, shortly after her mother’s death, she was diagnosed with brain and throat cancer and seldom appeared in public afterwards; and her death on November 12, 1994. https://tennesseeencyclopedia.net/entries/wilma-rudolph-1940-1994-and-the-tsu-tigerbelles/
4. “Rudolph, Wilma (1940–1994),” *Women in World History: A Biographical Encyclopedia* (Gale), via Encyclopedia.com. Supports her premature birth at 4.5 pounds; double pneumonia at four followed by scarlet fever; a mild form of polio that left a crooked, partly paralyzed left leg with the foot turned inward; two African American doctors at Meharry Medical College in Nashville who fitted a corrective metal brace and prescribed massage and heat; weekly bus trips with her mother, in the back of the bus, for several years, and massage by her family several times a day; taking the brace off in public at 9½ and returning it by 12; and her death of brain cancer at her home in Brentwood, Tennessee, on November 12, 1994. https://www.encyclopedia.com/women/encyclopedias-almanacs-transcripts-and-maps/rudolph-wilma-1940-1994
5. Olympedia. “Wilma Rudolph” (athlete profile). Supports her full name, birth on June 23, 1940, in Saint Bethlehem, death on November 12, 1994, in Brentwood, Tennessee, at 54, of a brain tumor; polio “as an infant”; and her results: 4 x 100 m relay bronze in 1956, and gold in the 100 m, 200 m and 4 x 100 m relay in 1960. https://www.olympedia.org/athletes/77958
6. *Deseret News*. “Former Olympic sprinter Wilma Rudolph dies at 54,” November 13, 1994. Obituary: supports that she died of brain cancer at her home, that she “had been in and out of hospitals for more than five months as the cancer spread,” that leg braces kept her from walking until about nine, her three gold medals in Rome, and her birth in Clarksville as the 20th of 22 children. https://www.deseret.com/1994/11/13/19142355/former-olympic-sprinter-wilma-rudolph-dies-at-54
7. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425
2. Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol* 2021;18(3):170-186 (PMID 33293629). https://pubmed.ncbi.nlm.nih.gov/33293629/
3. Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol* 2021;23(8):1231-1251 (PMID 34185076). https://pubmed.ncbi.nlm.nih.gov/34185076/
4. Mohile NA, et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. *J Clin Oncol* 2022;40(4):403-426 (PMID 34898238). https://pubmed.ncbi.nlm.nih.gov/34898238/
5. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;352(10):987-996 (PMID 15758009). https://pubmed.ncbi.nlm.nih.gov/15758009/ ; Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;352(10):997-1003 (PMID 15758010). https://pubmed.ncbi.nlm.nih.gov/15758010/
6. Stupp R, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (EF-14). *JAMA* 2017;318(23):2306-2316 (PMID 29260225). https://pubmed.ncbi.nlm.nih.gov/29260225/
7. TEMODAR (temozolomide) prescribing information, DailyMed: 75 mg/m2 daily for 42 to 49 days with radiotherapy, then 150 mg/m2 on days 1 to 5 of a 28-day cycle with escalation to 200 mg/m2 from cycle 2; weekly blood counts during the concurrent phase and on day 22 of each maintenance cycle; Pneumocystis prophylaxis during the concurrent phase and while lymphopenia lasts; liver tests at baseline, midway through the first cycle, before each cycle and two to four weeks after the last dose. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=046a9011-3911-4d3f-a15f-fbb56d5aad56
8. Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. *J Clin Oncol* 2023 (PMID 37774317). https://pubmed.ncbi.nlm.nih.gov/37774317/
9. Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. *Neuro Oncol* 2021;23(11):1835-1844 (PMID 34174071). https://pubmed.ncbi.nlm.nih.gov/34174071/
10. Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. *J Clin Oncol* 2023;41(16):3063-3071 (PMID 37075273). https://pubmed.ncbi.nlm.nih.gov/37075273/
11. Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. *J Clin Oncol* 2024;42(19):2336-2357 (PMID 38748941). https://pubmed.ncbi.nlm.nih.gov/38748941/
12. Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. *Eur J Neurol* 2006;13(8):795-801 (PMID 16879288). https://pubmed.ncbi.nlm.nih.gov/16879288/
13. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), depression monograph (PHQ-2 and PHQ-9 screening and reassessment). The CMID has no brain tumor monograph, so the specialty guidelines above govern the cancer care. https://patrickrutledge.github.io/topthirty/
14. U.S. Preventive Services Task Force: A and B recommendations, depression (2023), breast cancer (2024), cervical cancer (2018), colorectal cancer (2021) and osteoporosis (2025); CDC Adult Immunization Schedule by Medical Condition and Other Indication; Medicare Preventive Services reference (Aether Forge, 2026). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations

## Editorial resolutions

- **Recent-death rule.** Rudolph died in 1994, so the rule applies. The case uses only what was reported publicly during her life or in obituaries and reference accounts: the *Deseret News* obituary, the National Women’s History Museum, the U.S. Olympic & Paralympic Museum, the *Tennessee Encyclopedia*, *Women in World History* and Olympedia. Her childhood illnesses come from these accounts and from her own published account of being told she would never walk (quoted by the museums). No sick visit is added. Her death is recorded once (CLM-0010), in plain words. No claim concerns mental health or substance use; the modern mood screens are synthetic and below the threshold for a safety assessment.
- **What is not public.** The type, location, grade and treatment of her brain cancer were never made public. Every clinical detail in the modern episode (the symptoms, the MRI, the left frontal location, glioblastoma, IDH-wildtype, MGMT methylation, the surgery, chemoradiation, tumor-treating fields, all values) is synthetic and is not a claim about her real illness. The throat cancer reported by two sources is recorded in CLM-0009 without detail and is not used in the modern episode.
- **Choice of modern episode.** Option (a), a primary brain tumor, was chosen: brain cancer is documented as her cause of death, and no source fetched describes new weakness, fatigue or pain in adult life, so post-polio syndrome (option b) has no public basis. Polio survivorship is kept in the history (PMH-003 to PMH-005), on the problem list as late effects of poliomyelitis (B91, linked to the polio claims), and in the modern frame as a factor in mobility and falls: the new right-sided weakness from the left frontal tumor adds to a left leg weakened in childhood, and each visit checks for new symptoms that could signal post-polio syndrome (none are found). The modern finding of a slightly smaller left calf is synthetic.
- **Glioblastoma rather than another tumor.** A primary brain tumor in a woman of 54 is most often glioblastoma, and glioblastoma teaches the full WHO CNS5 integrated diagnosis and the Stupp protocol. MGMT promoter methylation and a gross total resection were chosen so that the course teaches standard treatment, tumor-treating fields and the first post-treatment MRI without progression; the record ends during adjuvant cycle 1, before her real death, and implies nothing about the course of her real illness.
- **Real people.** No relative is named in the modern episode, and no decision, statement or health fact is attributed to a relative. Her mother appears only in the documented history (the bus trips to Nashville and her own published words about her mother), and in CLM-0009, which follows the *Tennessee Encyclopedia* in dating the diagnosis to shortly after her mother’s death without any health fact about her mother. Her four children are mentioned in the modern social history only as “four grown children” (the obituary says she was survived by two sons and two daughters). The modern family history is left empty. Other athletes, coaches and officials named in the sources are not used.
- **Conflicts.** (1) Birthplace: Saint Bethlehem (Olympedia, the U.S. Olympic & Paralympic Museum, the National Women’s History Museum) or Clarksville (the *Tennessee Encyclopedia*, the *Deseret News*); Saint Bethlehem is a community near Clarksville, and CLM-0001 gives both. (2) Age at polio: “as an infant” (Olympedia), about four (the museum, with pneumonia and scarlet fever at four) or five (secondary accounts not used); CLM-0004 states the range. (3) The brace: worn from six to ten (*Tennessee Encyclopedia*), taken off in public at 9½ and returned by 12 (*Women in World History*), braces that kept her from walking until about nine (*Deseret News*), and running by eleven (the museum); CLM-0006 records the range, and the past medical history says she walked without the brace by about twelve. (4) Length and frequency of the Meharry treatment: weekly for several years (*Women in World History*), weekly (the museum); other figures in secondary sites (twice a week, two years) are not used. (5) Cancer: brain cancer in every source; “brain and throat cancer” in the *Tennessee Encyclopedia* and the museum; Wikipedia states a diagnosis in July 1994 without a citation, and a search summary attributed that date to a relative quoted in *The New York Times*, so the month is not used and the diagnosis is dated only to 1994. (6) Why the family went to Nashville: the museum says it was the closest place with doctors who would treat her in the segregated South; no source fetched states that a Clarksville hospital refused her, so CLM-0005 uses the museum’s wording.
- **Sources not used.** *The New York Times* obituary (Litsky, November 13, 1994) and Britannica returned access errors and are not cited; a copy of the *Times* obituary hosted by a third party was not read. Her 1977 autobiography *Wilma* was not available; it is used only through the museums’ quotation of it, and its title and year are not stated as a claim. The Tennessee State Library and Archives was searched without finding a page on her medical history.
- **Index age and dates.** The index visit on June 29, 2026 maps to June 29, 1994, six days after her 54th birthday and before the 1994 diagnosis, which the sources date to shortly after her mother’s death. The synthetic date of birth is June 23, 1972 (shift 32 years). The chronic-care visits on July 2, July 29, September 14 and October 9, 2026, the surgery on July 8, radiotherapy from August 3 to September 11, and the preventive visit on October 29, 2026 (age 54, so a periodic adult preventive visit) map to the same days of 1994, before her death on November 12. The presenting-problem pattern is used: the symptoms are a resolved problem (R29.818) when the MRI shows a mass at visit 2; the mass is a resolved problem (D49.6) when the pathology gives the diagnosis at visit 3; glioblastoma (C71.1) is recorded at visit 3. The claims about her diagnosis and death are linked to the November 1994 timeline event, so the intake documents do not show them.
- **Equity.** As a child she was taken by bus to Nashville, a 90-minute round trip, for care at a historically Black medical school, because no closer doctor would treat her in the segregated South. The modern episode does not invent statistics about disparities in brain tumor care; it models prompt imaging, specialist review within three days, complete access to mapping surgery, molecular testing, tumor-treating fields and trial screening, and plain explanation. Her own published account of being told as a child that she would never walk is used, with care, for her wish to be told the facts plainly.
- **Synthetic clinical picture and teaching points.** Dexamethasone is started only for edema causing symptoms and tapered off within five weeks of surgery, with steroid-induced hyperglycemia (R73.9) that resolves after the taper. No prophylactic antiseizure drug is given because she never has a seizure. Hospital thrombosis prophylaxis is given after surgery, with no routine prophylaxis at home. Temozolomide is given for 42 days (the label’s 42 to 49), continuing to the Sunday after the last radiotherapy fraction. Lymphopenia from temozolomide (D72.810) keeps Pneumocystis prophylaxis going. She chooses tumor-treating fields at the end of chemoradiation and starts them with adjuvant cycle 1. Early palliative care is referred at the end of chemoradiation and seen two weeks later. Qualitative results (pathology, molecular markers, MRI, CT, hepatitis and HIV serology) appear only in procedure and note text. Height (180 cm) and weights are synthetic.
- **Preventive visit.** A periodic adult preventive visit at 54 (CPT 99396 with 99497 in plain text) on day 21 of adjuvant cycle 1, with the day-22 blood count drawn a day early. Judgment calls: breast, cervical and colorectal screening shown as up to date (synthetic), with the next rounds to be decided with her in light of her illness; lipid screening declined by her for now; bone density not indicated at 54 after under two months of dexamethasone without a fracture; inactivated influenza vaccine, PCV20 and recombinant zoster dose 1 given during chemotherapy, with no live vaccines; COVID-19 vaccine due at her pharmacy (no product code recorded). Advance care planning records only her general preferences and an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (three days with the MRI and consultation, three weeks after surgery, the end of chemoradiation, and day 1 of adjuvant temozolomide) are documented as focused visits on the NCCN CNS cancers guideline, the EANO 2021 diffuse glioma guideline, the ASCO-SNO guideline, WHO CNS5, the Stupp and EF-14 trials, the temozolomide label, RANO 2.0, the SNO-EANO seizure guideline, the ASCO thrombosis and palliative care guidelines, the EFNS post-polio guideline and the CMID depression monograph. Two deviations are recorded instead of invented results: (1) the weekly blood count in week 6 of chemoradiation was not drawn because the standing order fell on a holiday Monday and was not moved; no harm resulted (counts a week later were above the thresholds for stopping temozolomide, with no bleeding or fever), and standing orders were tied to treatment days; (2) the liver tests the label calls for midway through the first adjuvant cycle were planned, to spare her a trip, for the day-21 draw about a week late; they were normal (ALT 33, AST 29 U/L). Synthetic findings introduced: steroid leukocytosis and hyperglycemia, grade 1 thrombocytopenia, grade 2 lymphopenia and a grade 1 transaminase rise at the end of chemoradiation, grade 1 radiation dermatitis, and grade 1 scalp redness under the tumor-treating fields arrays.
- **Consultation.** The neuro-oncology referral, written at intake when only the symptoms and examination were known, and the consultation by Tomasz Brzezinski, MD (a fictional consultant), with the neurosurgery team on the day of the three-day visit, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: functional MRI and awake craniotomy with mapping for maximal safe resection, an MRI within 48 hours, the integrated WHO CNS5 diagnosis with MGMT, radiotherapy with temozolomide and then adjuvant temozolomide with tumor-treating fields, steroid taper, no seizure prophylaxis, hospital thrombosis prophylaxis, and the monitoring primary care shares.
